Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 141 publications
Overcoming Trial Exclusion: A Multicenter Analysis of Hemodialysis Multiple Myeloma Patients Who Underwent BCMA-Directed CAR-T Therapy.
Journal: Current oncology (Toronto, Ont.)
Published: June 27, 2026
BRIDGE-2M: Optimizing Bridging Therapy Prior to CAR-T Therapy in Multiple Myeloma: A Modified Double-Blind Delphi Panel of US Physicians.
Journal: Advances in therapy
Published: June 01, 2026
Quad-Exposed/Refractory Multiple Myeloma: Patients Previously Treated With Anti-CD38, IMiDs, Proteasome Inhibitors, and BCMA-Targeted Therapies.
Journal: Clinical lymphoma, myeloma & leukemia
Published: March 16, 2026
Consolidation Therapy with Checkpoint Inhibitors After Autologous Hematopoietic Cell Transplantation in Patients with High-Risk Multiple Myeloma and Lymphoma.
Journal: Transplantation and cellular therapy
Published: March 11, 2026
Efficacy and safety of elranatamab in patients with relapsed or refractory multiple myeloma: A US subgroup analysis from MagnetisMM-3.
Journal: Cancer
Published: January 16, 2026
Salvage Therapy in Multiple Myeloma With Prior T-Cell Engager Exposure: Talquetamab, Elranatamab or Teclistamab in Combination With Pomalidomide.
Journal: European journal of haematology
Published: January 09, 2026
Real-world outcomes of patients with relapsed refractory multiple myeloma treated with commercial bispecific T-cell engager antibodies: a single center experience.
Journal: Leukemia & lymphoma
Published: December 02, 2025
Vestibular Symptoms Following Talquetamab Therapy in Heavily Pretreated Multiple Myeloma.
Journal: Blood advances
Published: November 03, 2025
Vestibular symptoms after talquetamab therapy in heavily pretreated multiple myeloma.
Journal: Blood advances
Published: November 03, 2025
Last Updated: 09/26/2026